Overview

GSK573719 IV Enabling Study

Status:
Completed
Trial end date:
2010-06-09
Target enrollment:
Participant gender:
Summary
A single-centre, open-label, sequential, cross-over study to examine the safety, tolerability and pharmacokinetics of 3 ascending single intravenous doses, a single 1000μg oral dose and a single 1000μg inhaled dose of GSK573719 in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline